US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
US20030113316A1
(en)
|
2001-07-25 |
2003-06-19 |
Kaisheva Elizabet A. |
Stable lyophilized pharmaceutical formulation of IgG antibodies
|
ES2536709T3
(es)
|
2002-02-14 |
2015-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
Utilización de ácido acético para eliminar los problemas inducidos por el ión Fe en las formulaciones de anticuerpos anti-HM1.24 o anti-IL6R
|
WO2003086443A1
(en)
|
2002-04-11 |
2003-10-23 |
Medimmune Vaccines, Inc. |
Spray freeze dry of compositions for intranasal administration
|
CA2482448C
(en)
|
2002-04-11 |
2014-07-08 |
Medimmune Vaccines, Inc. |
Preservation of bioactive materials by freeze dried foam
|
CA2484052C
(en)
|
2002-04-11 |
2011-06-14 |
Medimmune Vaccines, Inc. |
Preservation of bioactive materials by spray drying
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2011226771B2
(en)
|
2002-06-14 |
2012-10-04 |
Medimmune, Llc |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
JP2005532395A
(ja)
|
2002-07-02 |
2005-10-27 |
スミスクライン・ビーチャム・コーポレイション |
新規な安定処方
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US7055598B2
(en)
|
2002-08-26 |
2006-06-06 |
Halliburton Energy Services, Inc. |
Fluid flow control device and method for use of same
|
US20040247588A1
(en)
|
2002-08-28 |
2004-12-09 |
Johnson Robert E. |
Formulations of modified antibodies and methods of making the same
|
AU2003291689A1
(en)
|
2002-10-31 |
2004-05-25 |
Protein Design Labs, Inc. |
Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
|
WO2004055164A2
(en)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
US20050053666A1
(en)
|
2002-12-31 |
2005-03-10 |
Stelios Tzannis |
Antibody-containing particles and compositions
|
US20040208869A1
(en)
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
ES2349779T5
(es)
|
2003-04-04 |
2013-11-26 |
Genentech, Inc. |
Formulaciones de anticuerpos y de proteínas a concentración elevada
|
KR101424624B1
(ko)
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
CA2526402A1
(en)
|
2003-06-05 |
2005-01-20 |
Genentech, Inc. |
Blys antagonists and uses thereof
|
CA2530263C
(en)
|
2003-08-12 |
2012-04-17 |
Eli Lilly And Company |
Medication dispensing apparatus with triple screw threads for mechanical advantage
|
DK1698640T4
(da)
|
2003-10-01 |
2019-09-02 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.
|
AR046639A1
(es)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
AR046774A1
(es)
|
2003-12-24 |
2005-12-21 |
Boehringer Ingelheim Pharma |
Formulacion liofilizada de conjugados de anticuerpos
|
ES2553987T3
(es)
|
2003-12-25 |
2015-12-15 |
Kyowa Hakko Kirin Co., Ltd. |
Preparación farmacéutica de base acuosa estable que contiene anticuerpo
|
TW200539855A
(en)
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
CA2557897C
(en)
|
2004-03-30 |
2012-08-28 |
Eli Lilly And Company |
Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
|
EP1755673B1
(en)
|
2004-04-12 |
2014-07-23 |
MedImmune, LLC |
Anti-il-9 antibody formulations and uses thereof
|
US8658203B2
(en)
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
US20070196364A1
(en)
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
DE602005022928D1
(de)
|
2004-11-30 |
2010-09-23 |
Abgenix Inc |
Antikörper gegen gpnmb und ihre verwendungen
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
CA2604840A1
(en)
|
2005-04-18 |
2006-10-26 |
Xtl Biopharmaceuticals Ltd. |
Stabilized anti-hepatitis b (hbv) antibody formulations
|
AU2006255415B2
(en)
|
2005-06-07 |
2011-10-06 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Stable and soluble antibodies inhibiting TNFalpha
|
SG162788A1
(en)
|
2005-06-14 |
2010-07-29 |
Amgen Inc |
Self-buffering protein formulations
|
KR20080019249A
(ko)
|
2005-06-15 |
2008-03-03 |
쉐링 코포레이션 |
안정한 항체 제형
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
EA014513B1
(ru)
|
2005-08-03 |
2010-12-30 |
Иммьюноджен, Инк. |
Композиция иммуноконъюгата
|
WO2007037795A2
(en)
|
2005-08-05 |
2007-04-05 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
DOP2005000210A
(es)
|
2005-10-19 |
2006-04-30 |
Genentech Inc |
Antibony formulations
|
US20070172520A1
(en)
|
2005-11-18 |
2007-07-26 |
University Of South Florida |
Immunotargeting of Nonionic Surfactant Vesicles
|
KR20080071192A
(ko)
|
2005-11-22 |
2008-08-01 |
와이어쓰 |
면역글로불린 융합 단백질 제형
|
EA014298B1
(ru)
*
|
2005-12-13 |
2010-10-29 |
Эли Лилли Энд Компани |
Анти-il-17-антитела
|
AU2006330858A1
(en)
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
CA2642270A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Antibody formulation
|
MX2008013535A
(es)
|
2006-04-21 |
2008-10-29 |
Amgen Inc |
Agentes amortiguadores para formulaciones biofarmaceuticas.
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
BRPI0713421A2
(pt)
|
2006-06-14 |
2012-03-13 |
Imclone Systems Incorporated |
Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
|
TW200826974A
(en)
|
2006-09-07 |
2008-07-01 |
Kirin Pharma Kk |
Stable lyophilized pharmaceutical preparation comprising antibody
|
JP2010504361A
(ja)
|
2006-09-25 |
2010-02-12 |
メディミューン,エルエルシー |
安定した抗体製剤およびその使用
|
AU2007307107B2
(en)
|
2006-10-06 |
2011-11-03 |
Amgen Inc. |
Stable antibody formulations
|
TW200833357A
(en)
|
2006-10-20 |
2008-08-16 |
Amgen Inc |
Stable polypeptide formulations
|
DE102006053375A1
(de)
|
2006-11-10 |
2008-05-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Mischung von Pulvern
|
TW200831133A
(en)
|
2006-12-11 |
2008-08-01 |
Hoffmann La Roche |
Mab Abeta lyophylized formulation
|
EP2129401B8
(en)
|
2006-12-21 |
2020-01-15 |
Amgen Inc. |
Stable buffered formulations containing polypeptides
|
WO2008086395A2
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
ES2627923T3
(es)
|
2007-01-11 |
2017-08-01 |
Novo Nordisk A/S |
Anticuerpos anti-KIR, formulaciones y usos de los mismos
|
BRPI0809112A2
(pt)
|
2007-03-22 |
2014-08-26 |
Imclone Llc |
Formulações estáveis de anticorpos
|
CA2682170A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
AR067010A1
(es)
*
|
2007-06-14 |
2009-09-30 |
Elan Pharm Inc |
Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
US20110014676A1
(en)
|
2007-06-29 |
2011-01-20 |
Battelle Memorial Institute |
Protein stabilization
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
ES2962777T3
(es)
|
2007-11-15 |
2024-03-21 |
Amgen Inc |
Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
TW200938221A
(en)
|
2007-11-30 |
2009-09-16 |
Abbott Lab |
Protein formulations and methods of making same
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
US20090324586A1
(en)
|
2008-06-26 |
2009-12-31 |
Wyeth |
Lyophilization cycle robustness strategy
|
WO2010017296A1
(en)
|
2008-08-05 |
2010-02-11 |
Wyeth |
Lyophilization above collapse
|
CN102202655B
(zh)
|
2008-08-27 |
2013-06-19 |
默沙东公司 |
基因工程抗IL-23p19抗体的冻干制剂
|
MX2011003013A
(es)
|
2008-09-19 |
2011-04-11 |
Pfizer |
Formulacion liquida estable de anticuerpos.
|
SG2014011365A
(en)
|
2008-09-19 |
2014-05-29 |
Hoffmann La Roche |
Novel antibody formulation
|
US20110256149A1
(en)
|
2008-10-09 |
2011-10-20 |
Medimmune, Llc |
Antibody formulation
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
PE20120169A1
(es)
|
2008-11-17 |
2012-02-29 |
Genentech Inc |
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
|
EP2358394A4
(en)
|
2008-11-17 |
2013-03-06 |
Genentech Inc |
METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULE UNDER PHYSIOLOGICAL CONDITIONS
|
AU2009316592B2
(en)
|
2008-11-20 |
2016-01-07 |
Genentech, Inc. |
Therapeutic protein formulations
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
NZ606283A
(en)
|
2008-11-28 |
2014-08-29 |
Abbvie Inc |
Stable antibody compositions and methods for stabilizing same
|
SG172004A1
(en)
*
|
2008-12-09 |
2011-07-28 |
Hoffmann La Roche |
Method for obtaining an excipient-free antibody solution
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
WO2010069858A1
(en)
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
FR2944448B1
(fr)
|
2008-12-23 |
2012-01-13 |
Adocia |
Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Il-17結合蛋白
|
EP2403873A1
(en)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
AR075715A1
(es)
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
RU2011140486A
(ru)
|
2009-03-06 |
2013-04-20 |
МЕДИММЬЮН, ЭлЭлСи |
Композиции, содержащие гуманизированные антитела к cd19
|
WO2010113943A1
(ja)
|
2009-03-31 |
2010-10-07 |
デンカ生研株式会社 |
免疫分析方法及びそのための試薬
|
JP2010241718A
(ja)
|
2009-04-03 |
2010-10-28 |
Kyowa Hakko Kirin Co Ltd |
安定な抗体の水溶液製剤
|
WO2010148117A1
(en)
|
2009-06-17 |
2010-12-23 |
Scantibodies Laboratory, Inc. |
Therapeutic and diagnostic affinity purified specific polyclonal antibodies
|
WO2010148321A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Slow dissolution method for reconstitution of lyophilized material
|
CA2764180A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
US20120183531A1
(en)
|
2009-07-14 |
2012-07-19 |
Biogen Idee Ma Inc |
Methods for Inhibiting Yellow Color Formation in a Composition
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
US20110059079A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
WO2011061712A1
(en)
|
2009-11-20 |
2011-05-26 |
Biocon Limited |
Formulations of antibody
|
CA2783715A1
(en)
|
2009-12-29 |
2011-07-07 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
EP3295957B1
(en)
|
2010-01-15 |
2019-08-07 |
Kirin-Amgen, Inc. |
Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
|
AU2011221472B2
(en)
|
2010-03-01 |
2013-08-29 |
Eli Lilly And Company |
Automatic injection device with delay mechanism including dual functioning biasing member
|
JP5937523B2
(ja)
|
2010-03-01 |
2016-06-22 |
サイトダイン インコーポレイテッドCytoDyn, Inc. |
濃縮されたタンパク質製剤およびその使用
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
NZ602054A
(en)
|
2010-03-17 |
2014-10-31 |
Abbott Res Bv |
Anti-nerve growth factor (ngf) antibody compositions
|
WO2011141926A2
(en)
|
2010-05-10 |
2011-11-17 |
Intas Biopharmaceuticals Limited |
Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
|
ME02819B
(me)
|
2010-05-14 |
2018-01-20 |
Amgen Inc |
Formulacije sa visokom koncentracijom antitijela
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
SG186421A1
(en)
|
2010-07-02 |
2013-01-30 |
Medimmune Llc |
Antibody formulations
|
JOP20190250A1
(ar)
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
FR2962650B1
(fr)
|
2010-07-19 |
2013-04-05 |
Lab Francais Du Fractionnement |
Composition d'immunoglobulines humaines concentrees
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
CN103119448A
(zh)
|
2010-09-17 |
2013-05-22 |
Abbvie公司 |
用于生物过程操作的拉曼光谱
|
PL2624865T3
(pl)
|
2010-10-06 |
2018-11-30 |
Regeneron Pharmaceuticals, Inc. |
Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
|
KR20180129991A
(ko)
|
2010-11-05 |
2018-12-05 |
노파르티스 아게 |
Il-17 길항제를 사용한 류마티스성 관절염의 치료 방법
|
AU2011325974B2
(en)
*
|
2010-11-11 |
2016-10-27 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-TNFalpha antibody liquid formulations
|
US20140031769A1
(en)
|
2010-11-19 |
2014-01-30 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
WO2012076670A2
(en)
|
2010-12-10 |
2012-06-14 |
Novartis Ag |
Antibody formulation
|
EP2471554A1
(en)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
EP2500035A1
(en)
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmaceutical formulation containing immunglobulin
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
EP3398612A1
(en)
|
2011-03-31 |
2018-11-07 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
CN107998388B
(zh)
|
2011-05-02 |
2023-07-14 |
千禧制药公司 |
抗α4β7抗体的制剂
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
AR086823A1
(es)
|
2011-06-30 |
2014-01-22 |
Genentech Inc |
Formulaciones de anticuerpo anti-c-met, metodos
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
CN107233569B
(zh)
|
2011-10-25 |
2021-08-31 |
普罗西纳生物科学有限公司 |
抗体制剂和方法
|
CN109078182B
(zh)
|
2011-10-31 |
2022-08-12 |
弗·哈夫曼-拉罗切有限公司 |
抗体制剂
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
TW201332574A
(zh)
|
2011-12-23 |
2013-08-16 |
Mersana Therapeutics Inc |
煙曲黴素衍生物-phf共軛物之醫藥調配物
|
CN104169299B
(zh)
|
2012-01-23 |
2018-06-05 |
瑞泽恩制药公司 |
含抗Ang-2 抗体的稳定化制剂
|
SG10201609982PA
(en)
|
2012-03-07 |
2017-01-27 |
Cadila Healthcare Ltd |
Pharmaceutical formulations of tnf-alpha anitbodies
|
EP2822640B1
(en)
|
2012-03-07 |
2020-02-05 |
DEKA Products Limited Partnership |
Infusion pump assembly
|
UA114620C2
(uk)
*
|
2012-03-07 |
2017-07-10 |
Елі Ліллі Енд Компані |
Фармацевтична композиція, яка містить анти-il-17-антитіло
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
SG11201407512VA
(en)
|
2012-05-18 |
2014-12-30 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
JP2015519382A
(ja)
|
2012-06-12 |
2015-07-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
治療用抗体のための医薬処方物
|
WO2014004436A2
(en)
|
2012-06-27 |
2014-01-03 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human il-23 antibodies
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
TW202042841A
(zh)
*
|
2012-09-07 |
2020-12-01 |
美商柯赫勒斯生物科學有限公司 |
阿達木單抗(adalimumab)之穩定水性調配物
|
MX2015004668A
(es)
|
2012-10-25 |
2015-07-23 |
Medimmune Llc |
Formulacion estable de anticuerpos de baja viscosidad.
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
EP2914289B1
(en)
|
2012-10-31 |
2019-05-22 |
Takeda GmbH |
Lyophilized formulation comprising gm-csf neutralizing compound
|
TW202033215A
(zh)
|
2012-11-01 |
2020-09-16 |
美商艾伯維有限公司 |
穩定雙重可變區域免疫球蛋白蛋白質調配物
|
US20150307606A1
(en)
|
2012-12-13 |
2015-10-29 |
Ashwin Basarkar |
Lyophilized spherical pellets of anti-il-23 antibodies
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
WO2014099636A1
(en)
|
2012-12-18 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-tnf alpha antibody
|
SG11201504897YA
(en)
|
2012-12-21 |
2015-07-30 |
Glenmark Pharmaceuticals Sa |
Anti her2 antibody formulation
|
WO2014124227A1
(en)
|
2013-02-07 |
2014-08-14 |
Immunomedics, Inc. |
Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
EP3888671A3
(en)
|
2013-03-11 |
2022-01-05 |
Amgen Inc. |
Protein formulations
|
KR102274714B1
(ko)
|
2013-03-13 |
2021-07-09 |
씨젠 인크. |
사이클로덱스트린 및 항체-약물 포합체 제형
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
EP2968538A1
(en)
|
2013-03-15 |
2016-01-20 |
Bayer HealthCare LLC |
Anti-prolactin receptor antibody formulations
|
EP2968535A2
(en)
|
2013-03-15 |
2016-01-20 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Low concentration antibody formulations
|
RU2020125266A
(ru)
|
2013-03-15 |
2020-09-24 |
Эббви Дойчланд Гмбх Унд Ко. Кг |
Составы конъюгата антитело против egfr-лекарственное средство
|
CN105189559B
(zh)
|
2013-03-15 |
2021-07-13 |
塔科达有限责任公司 |
抗体制剂及其用途
|
US9700485B2
(en)
*
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
AU2014276460A1
(en)
|
2013-06-04 |
2015-12-24 |
Vyome Biosciences Pvt. Ltd. |
Coated particles and compositions comprising same
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
KR102435648B1
(ko)
|
2013-09-11 |
2022-08-25 |
이글 바이오로직스 인코퍼레이티드 |
점도저하제를 함유하는 액체 단백질 제형
|
UA122478C2
(uk)
|
2013-09-27 |
2020-11-25 |
Дженентек, Інк. |
Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
|
ES2893861T3
(es)
|
2013-10-24 |
2022-02-10 |
Astrazeneca Ab |
Formulaciones de anticuerpo estables, acuosas
|
US10617764B2
(en)
|
2013-11-21 |
2020-04-14 |
Genmab A/S |
Lyophilized anti-tissue factor antibody-drug conjugates
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
US20150225479A1
(en)
|
2014-02-12 |
2015-08-13 |
Sanofi |
Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
|
US20150274819A1
(en)
|
2014-03-03 |
2015-10-01 |
La Jolla Biologics, Inc. |
Stable aqueous recombinant protein formulations
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
CN106459140B
(zh)
|
2014-03-11 |
2019-12-10 |
株式会社绿十字控股 |
用于纯化免疫球蛋白的方法
|
CA2941232C
(en)
|
2014-03-11 |
2020-08-25 |
Green Cross Holdings Corporation |
Method for purifying immunoglobulin
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
EP3126386A1
(en)
|
2014-03-31 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
KR20160130248A
(ko)
|
2014-03-31 |
2016-11-10 |
키린-암젠, 인코포레이티드 |
손발톱 및 두피 건선의 치료 방법
|
WO2015151115A1
(en)
|
2014-04-02 |
2015-10-08 |
Intas Pharmaceuticals Limited |
Liquid pharmaceutical composition of adalimumab
|
AU2015243993A1
(en)
|
2014-04-07 |
2016-09-15 |
Seattle Genetics, Inc. |
Stable formulations for anti-CD19 antibodies and antibody-drug conjugates
|
JP2015209384A
(ja)
|
2014-04-24 |
2015-11-24 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
医薬製剤
|
ES2960599T3
(es)
|
2014-06-26 |
2024-03-05 |
Amgen Inc |
Formulaciones de proteínas
|
EP3179985A1
(en)
|
2014-08-14 |
2017-06-21 |
Brown University |
Compositions for stabilizing and delivering proteins
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
CN106604744A
(zh)
|
2014-09-03 |
2017-04-26 |
免疫医疗有限公司 |
稳定的抗IL‑4R‑α抗体配制品
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
MX2017004986A
(es)
|
2014-10-17 |
2017-08-18 |
Amgen Inc |
Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2 para terapias oculares.
|
RU2017111228A
(ru)
*
|
2014-10-18 |
2018-11-21 |
Пфайзер Инк. |
Композиции антитела против IL-7R
|
TWI705827B
(zh)
|
2014-11-07 |
2020-10-01 |
瑞士商諾華公司 |
治療眼部疾病之方法
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
US20170360929A1
(en)
|
2014-12-23 |
2017-12-21 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
EP3240571A4
(en)
|
2014-12-31 |
2018-06-13 |
NovelMed Therapeutics, Inc. |
Formulation of aglycosylated therapeutic antibodies
|
MX2017009759A
(es)
|
2015-01-28 |
2017-10-27 |
Pfizer |
Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
|
KR20170115090A
(ko)
|
2015-02-09 |
2017-10-16 |
유씨비 바이오파마 에스피알엘 |
약학 제제
|
RU2017131618A
(ru)
|
2015-02-13 |
2019-03-13 |
Санофи |
Стабильный жидкий состав для моноклональных антител
|
EA201792273A1
(ru)
|
2015-04-17 |
2018-04-30 |
Бристол-Маерс Сквибб Компани |
Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
BR112017025264A2
(pt)
*
|
2015-07-16 |
2018-08-07 |
Lilly Co Eli |
tratamento de prurido
|
EP4233892A3
(en)
|
2015-08-19 |
2023-10-25 |
Astrazeneca AB |
Stable anti-ifnar1 formulation
|
CN106474470B
(zh)
*
|
2015-08-28 |
2020-05-22 |
江苏恒瑞医药股份有限公司 |
一种抗il-17a抗体的组合物
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
EP3352790A1
(en)
|
2015-09-22 |
2018-08-01 |
Pfizer Inc |
Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
|
JP6921062B2
(ja)
|
2015-09-28 |
2021-08-18 |
スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド |
安定な抗pd−1抗体医薬製剤および医薬におけるその適用
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
EP3368565A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody formulations
|
CN106620690A
(zh)
|
2015-10-30 |
2017-05-10 |
上海抗体药物国家工程研究中心有限公司 |
一种稳定的抗体制剂
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
WO2017095848A1
(en)
|
2015-11-30 |
2017-06-08 |
Medimmune, Llc |
Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
EA201891339A1
(ru)
|
2015-12-07 |
2019-01-31 |
Мерк Патент Гмбх |
Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
|
EP3397281B1
(en)
|
2015-12-29 |
2020-09-09 |
Outlook Therapeutics, Inc. |
Buffered formulations of bevacizumab
|
US20190284282A1
(en)
|
2016-01-12 |
2019-09-19 |
Dr. Reddy's Laboratories Limited |
Stable pharmaceutical composition
|
CN109496149B
(zh)
|
2016-01-13 |
2022-10-14 |
根马布股份公司 |
抗体及其药物缀合物的制剂
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
EP3408293A4
(en)
*
|
2016-01-28 |
2019-09-11 |
Janssen Biotech, Inc. |
BISPECIFIC ANTI-TNF-ALPHA / IL-17A ANTIBODY ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS OF USE
|
AR103622A1
(es)
|
2016-02-05 |
2017-05-24 |
Ucb Biopharma Sprl |
Formulación farmaceutica
|
US20170240617A1
(en)
|
2016-02-24 |
2017-08-24 |
Visterra, Inc. |
Formulations of antibody molecules to influenza virus
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
WO2017165736A1
(en)
|
2016-03-25 |
2017-09-28 |
Visterra, Inc. |
Formulation of antibody molecules to dengue virus
|
JP6992262B2
(ja)
|
2016-03-31 |
2022-02-15 |
東ソー株式会社 |
変性抗体測定試薬の製造方法
|
AU2017250005B2
(en)
|
2016-04-12 |
2022-12-22 |
Swinburne University Of Technology |
Injectable composition for delivery of a biologically active agent
|
US20190060241A1
(en)
|
2016-04-13 |
2019-02-28 |
Medimmune, Llc |
Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
GB201608323D0
(en)
|
2016-05-12 |
2016-06-29 |
Ucb Biopharma Sprl |
Pharmaceutical compositions
|
TWI826351B
(zh)
|
2016-05-31 |
2023-12-21 |
大陸商鴻運華寧(杭州)生物醫藥有限公司 |
R抗體,其藥物組合物及其應用
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
WO2017214187A1
(en)
|
2016-06-07 |
2017-12-14 |
Aridis Pharmaceuticals, Inc. |
Method for preparation of quick dissolving thin films containing bioactive material with enhanced thermal stability
|
CN109415440B
(zh)
|
2016-06-27 |
2022-12-06 |
莫佛塞斯公司 |
抗-cd19抗体制剂
|
FI3479819T3
(fi)
|
2016-06-30 |
2024-04-17 |
Celltrion Inc |
Stabiili nestemäinen farmaseuttinen valmiste
|
KR102450280B1
(ko)
|
2016-07-05 |
2022-10-04 |
사노피 |
항체 제형
|
CN109476733A
(zh)
|
2016-07-19 |
2019-03-15 |
诺华股份有限公司 |
使用il-17拮抗剂治疗新发斑块型银屑病的方法
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
FR3056912B1
(fr)
|
2016-09-30 |
2019-12-27 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Procede d'inactivation virale d'une preparation d'anticorps monoclonaux
|
WO2018067987A1
(en)
|
2016-10-06 |
2018-04-12 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
IL310367A
(en)
|
2016-10-07 |
2024-03-01 |
Regeneron Pharma |
A stable protein at room temperature that has been lyophilized
|
WO2018116198A1
(en)
|
2016-12-23 |
2018-06-28 |
Serum Institute Of India Private Limited |
Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
|
EP3563863B1
(en)
|
2016-12-28 |
2023-07-12 |
JCR Pharmaceuticals Co., Ltd. |
Lyophilized preparation
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
CN108261391B
(zh)
|
2016-12-30 |
2022-03-01 |
江苏太平洋美诺克生物药业有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
CN108261544B
(zh)
|
2016-12-30 |
2023-05-05 |
江苏太平洋美诺克生物药业股份有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
AU2018207367B2
(en)
|
2017-01-11 |
2024-02-15 |
Celltrion Inc. |
Stable Liquid Formula
|
HUE052551T2
(hu)
|
2017-01-17 |
2021-05-28 |
Genentech Inc |
Szubkután HER2 antitest készítmények
|
AU2018209118A1
(en)
|
2017-01-19 |
2019-07-11 |
Bayer Pharma Aktiengesellschaft |
Novel stable formulation for FXIa antibodies
|
GB201703063D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
GB201703062D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
TWI761453B
(zh)
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
BR112019018022A2
(pt)
|
2017-03-01 |
2020-06-02 |
Medimmune Limited |
Formulações de anticorpos monoclonais
|
EP3372242A1
(en)
*
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
TW201834639A
(zh)
|
2017-03-06 |
2018-10-01 |
德商馬克專利公司 |
水性抗體調配物
|
UA123847C2
(uk)
*
|
2017-03-16 |
2021-06-09 |
Лг Кем, Лтд. |
Рідка композиція анти-tnf альфа антитіла
|
TW201836637A
(zh)
|
2017-03-29 |
2018-10-16 |
持田製藥股份有限公司 |
含有抗體之液體製劑
|
WO2018179138A1
(ja)
|
2017-03-29 |
2018-10-04 |
持田製薬株式会社 |
抗体含有液体製剤
|
KR20190141658A
(ko)
|
2017-03-29 |
2019-12-24 |
셀진 코포레이션 |
Pd-1 결합 단백질을 포함하는 제제 및 이의 제조 방법
|
KR20190129061A
(ko)
|
2017-03-31 |
2019-11-19 |
메이지 세이카 파루마 가부시키가이샤 |
수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
JOP20190255A1
(ar)
|
2017-04-28 |
2019-10-27 |
Amgen Inc |
صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
WO2018211517A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
CN110799545A
(zh)
|
2017-07-10 |
2020-02-14 |
拜耳制药股份公司 |
用于男性和女性模式脱发的催乳素受体抗体
|
CN107400164A
(zh)
|
2017-07-18 |
2017-11-28 |
中山和芯生物技术有限公司 |
一种含蔗糖的生物制品稳定剂及其制备方法和应用
|
WO2019018640A1
(en)
|
2017-07-21 |
2019-01-24 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
|
EP3658612A4
(en)
|
2017-07-25 |
2021-06-02 |
Elektrofi, Inc. |
TRAINING OF PARTICLES INCLUDING AGENTS
|
WO2019020069A1
(zh)
|
2017-07-27 |
2019-01-31 |
江苏恒瑞医药股份有限公司 |
一种sost抗体药物组合物及其用途
|
WO2019020745A1
(en)
|
2017-07-28 |
2019-01-31 |
F. Hoffmann-La Roche Ag |
BISPECIFIC ANTIBODY FORMULATION
|
CN111225686A
(zh)
|
2017-08-15 |
2020-06-02 |
普罗根尼蒂公司 |
使用可摄入装置释放免疫调节剂治疗炎性疾病
|
WO2019039483A1
(ja)
|
2017-08-23 |
2019-02-28 |
第一三共株式会社 |
抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法
|
AU2018328015A1
(en)
|
2017-09-05 |
2020-03-05 |
Merck Sharp & Dohme Corp. |
Compounds for reducing the viscosity of biological formulations
|
EP3459527B1
(en)
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
MA50670A
(fr)
|
2017-09-29 |
2020-08-05 |
Janssen Biotech Inc |
Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
|
JP7170983B2
(ja)
|
2017-10-13 |
2022-11-15 |
国立大学法人大阪大学 |
改善された保存安定性を有するタンパク質含有液体製剤およびその製造方法
|
CN109745559A
(zh)
|
2017-11-01 |
2019-05-14 |
三生国健药业(上海)股份有限公司 |
抗人il-17a的单克隆抗体的液体制剂
|
GB201718888D0
(en)
|
2017-11-15 |
2017-12-27 |
Ucb Biopharma Sprl |
Method
|
GB201719447D0
(en)
|
2017-11-23 |
2018-01-10 |
Ucb Biopharma Sprl |
Pharmaceutical composition
|
SG11202004187UA
(en)
|
2017-11-29 |
2020-06-29 |
Prothena Biosciences Ltd |
Lyophilized formulation of a monoclonal antibody against transthyretin
|
BR112020010761A2
(pt)
|
2017-11-30 |
2020-11-24 |
Bio-Thera Solutions, Ltd. |
formulação líquida de anticorpo humanizado para o tratamento de doenças relacionadas à il-6
|
JP2021506922A
(ja)
|
2017-12-22 |
2021-02-22 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Lag−3抗体医薬組成物およびその使用
|
WO2019157340A1
(en)
|
2018-02-08 |
2019-08-15 |
Amgen Inc. |
Low ph pharmaceutical antibody formulation
|
CA3093036A1
(en)
|
2018-03-07 |
2019-09-12 |
Pfizer Inc. |
Anti-pd-1 antibody compositions
|
US11427639B2
(en)
|
2018-04-02 |
2022-08-30 |
Richter Gedeon Nyrt. |
Antibody-containing aqueous formulation and use thereof
|
US20210087250A1
(en)
|
2018-04-06 |
2021-03-25 |
Cyprumed Gmbh |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
MA52657A
(fr)
|
2018-04-10 |
2021-02-17 |
Genmab As |
Anticorps spécifiques d'axl pour le traitement du cancer
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
EP3781199A1
(en)
|
2018-04-17 |
2021-02-24 |
Outlook Therapeutics, Inc. |
Buffered formulations of bevacizumab for use of treating diseases
|
BR112020020390A2
(pt)
|
2018-04-25 |
2021-01-19 |
Medimmune Limited |
Formulações de anticorpos anti-pd-l1 humanos
|
US11103552B2
(en)
|
2018-05-10 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
AU2019269131B2
(en)
|
2018-05-14 |
2024-02-22 |
Fundació Privada Institució Catalana De Recerca I Estudis Avançats |
Antibodies against LIF and dosage forms thereof
|
CN110538321B
(zh)
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
CA3100981A1
(en)
|
2018-06-01 |
2019-12-05 |
Rakuten Medical, Inc. |
Phthalocyanine dye conjugate compositions
|
US20210223262A1
(en)
|
2018-06-07 |
2021-07-22 |
Merck Sharp & Dohme Corp. |
Lyosphere critical reagent kit
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
EP3810085A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
CN112601541A
(zh)
|
2018-06-22 |
2021-04-02 |
比欧拉利克斯有限公司 |
口服给药的生物聚合物制剂
|
KR20210024082A
(ko)
|
2018-06-25 |
2021-03-04 |
제이씨알 파마 가부시키가이샤 |
단백질 함유 수성 액제
|
TW202011995A
(zh)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
EP3818062A4
(en)
|
2018-07-05 |
2022-03-16 |
Hangzhou Dac Biotech Co., Ltd |
CROSS-LINKED PYRROLOBENZODIAZEPINE DIMERE DERIVATIVE (PBD) AND ITS CONJUGATES
|
WO2020016417A1
(en)
|
2018-07-19 |
2020-01-23 |
Ichnos Sciences S.A. |
Liquid antibody formulation
|
US11730698B2
(en)
|
2018-07-19 |
2023-08-22 |
Celltrion Inc. |
Stable liquid pharmaceutical preparation
|
WO2020041532A1
(en)
|
2018-08-21 |
2020-02-27 |
Sf17 Therapeutics, Inc. |
Compositions and methods for treating progressive neurodegenerative diseases
|
WO2020053301A1
(en)
|
2018-09-11 |
2020-03-19 |
Ichnos Sciences S.A. |
Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
|
KR20210062027A
(ko)
|
2018-09-13 |
2021-05-28 |
에프. 호프만-라 로슈 아게 |
Csf-1r 항체 제제
|
AU2019355995A1
(en)
|
2018-10-05 |
2021-04-08 |
Five Prime Therapeutics, Inc. |
Anti-FGFR2 antibody formulations
|
CA3115747A1
(en)
|
2018-10-10 |
2020-04-16 |
Astellas Pharma Inc. |
Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
|
SG11202103424UA
(en)
|
2018-10-12 |
2021-05-28 |
Hangzhou Dac Biotech Co Ltd |
Conjugation linkers containing 2,3-diaminosuccinyl group
|
CA3115708A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
EP3870145A1
(en)
|
2018-10-26 |
2021-09-01 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
CR20210200A
(es)
|
2018-10-29 |
2021-05-25 |
Hoffmann La Roche |
Formulación de anticuerpos
|
MX2021005015A
(es)
|
2018-10-31 |
2021-07-21 |
Richter Gedeon Nyrt |
Formulaciones farmaceuticas acuosas.
|
CN113454111A
(zh)
|
2018-11-06 |
2021-09-28 |
健玛保 |
抗体配制剂
|
EP3876978A4
(en)
|
2018-11-07 |
2022-09-28 |
Merck Sharp & Dohme Corp. |
STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE
|
JP2022532965A
(ja)
|
2018-11-21 |
2022-07-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度タンパク質製剤
|
JP2022513684A
(ja)
|
2018-12-03 |
2022-02-09 |
アジェンシス,インコーポレイテッド |
抗191p4d12抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法
|
SG11202104012QA
(en)
|
2018-12-14 |
2021-05-28 |
Morphosys Ag |
Antibody formulations
|
US11639380B2
(en)
|
2019-01-08 |
2023-05-02 |
H. Lundbeck A/S |
Acute treatment and rapid treatment of headache using anti-CGRP antibodies
|
WO2020154704A2
(en)
|
2019-01-25 |
2020-07-30 |
Sio2 Medical Products, Inc. |
Common contact surfaces for use in the manufacture, packaging, delivery, and assessment of biopharmaceutical products
|
AU2019426942B2
(en)
|
2019-01-31 |
2023-11-16 |
Hangzhou Dac Biotech Co., Ltd |
A conjugate of an amanita toxin with branched linkers
|
WO2020160323A2
(en)
|
2019-01-31 |
2020-08-06 |
Elektrofi, Inc. |
Particle formation and morphology
|
CN113474360A
(zh)
|
2019-02-18 |
2021-10-01 |
伊莱利利公司 |
治疗性抗体制剂
|
TW202102260A
(zh)
|
2019-03-21 |
2021-01-16 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
CA3094194A1
(en)
|
2019-03-26 |
2020-09-26 |
Remegen Co., Ltd. |
Pharmaceutical formulations of her2 antibody-drug conjugate
|
JP2022521840A
(ja)
|
2019-04-01 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤を安定化するための組成物および方法
|
JP2022527542A
(ja)
|
2019-04-04 |
2022-06-02 |
ヤンセン バイオテツク,インコーポレーテツド |
抗IFN-α/ω抗体の投与方法
|
WO2020215021A1
(en)
|
2019-04-18 |
2020-10-22 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
EP3962942A1
(en)
|
2019-05-01 |
2022-03-09 |
Novo Nordisk A/S |
Anti-il-6 antibody formulation
|
CN110179746A
(zh)
|
2019-05-17 |
2019-08-30 |
通化东宝生物科技有限公司 |
一种稳定的苏金单抗注射剂及其制备方法
|
WO2020233534A1
(zh)
|
2019-05-17 |
2020-11-26 |
百奥泰生物制药股份有限公司 |
抗体-药物偶联物制剂、制备方法及应用
|
CA3141492A1
(en)
|
2019-05-24 |
2020-12-03 |
Sanofi |
Methods for treating systemic sclerosis
|
WO2020243346A1
(en)
|
2019-05-28 |
2020-12-03 |
The General Hospital Corporation |
Apoe antibodies, fusion proteins and uses thereof
|
WO2020247572A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Masked antibody formulations
|
CN110124030A
(zh)
|
2019-06-10 |
2019-08-16 |
通化东宝生物科技有限公司 |
一种苏金单抗注射液及其制备方法
|
US11655302B2
(en)
|
2019-06-10 |
2023-05-23 |
Sanofi |
Anti-CD38 antibodies and formulations
|
CN114245737A
(zh)
|
2019-06-11 |
2022-03-25 |
司斐股份有限公司 |
微乳剂组合物
|
WO2020257998A1
(en)
|
2019-06-24 |
2020-12-30 |
Hangzhou Dac Biotech Co., Ltd |
A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
|
EP3766481A1
(en)
|
2019-07-19 |
2021-01-20 |
Ichnos Sciences SA |
Liquid antibody formulation
|
EP3999537A1
(en)
|
2019-07-19 |
2022-05-25 |
Ichnos Sciences SA |
Lyophilized antibody formulation
|
CN112805566A
(zh)
|
2019-07-29 |
2021-05-14 |
上海谷森医药有限公司 |
用于吸入治疗肺癌的抗体类药物制剂
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
EP4031570A1
(en)
|
2019-09-20 |
2022-07-27 |
Novartis AG |
Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
|
CN110585430B
(zh)
|
2019-09-29 |
2023-09-08 |
华博生物医药技术(上海)有限公司 |
一种人源化抗人il-17a单克隆抗体的药物组合物
|
AU2020358101A1
(en)
|
2019-10-02 |
2022-04-28 |
Alamab Therapeutics, Inc. |
Anto-connexin antibody formulations
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
CN112891530B
(zh)
|
2020-06-19 |
2021-08-24 |
北京东方百泰生物科技股份有限公司 |
一种抗il-17ra单克隆抗体的注射制剂
|